Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 0.73 |
| ▸ | DRD3 | P35462 | 7/20 | 0.73 |
| ▸ | DRD2 | P14416 | 6/20 | 0.73 |
| ▸ | HTR2A | P28223 | 7/20 | 0.65 |
| ▸ | HTR7 | P34969 | 6/20 | 0.65 |
| ▸ | HTR1A | P08908 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917818 | 0.87 | DRD4 (0.71) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL32669452 | 0.86 | DRD4 (0.63) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL6363395 | 0.86 | DRD4 (0.63) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL857712 | 0.86 | DRD4 (0.74) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL5198732 | 0.85 | ALDH1A1 (0.65) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL5399421 | 0.85 | DRD4 (1.00) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL8858021 | 0.85 | DRD4 (0.77) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL32669409 | 0.84 | DRD4 (0.64) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL5198686 | 0.82 | DRD4 (1.00) | DRD4DRD3DRD2HTR2AHTR7 | |
| SCHEMBL5382639 | 0.81 | DRD4 (0.76) | DRD4DRD3DRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| CN-107208279-B | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10174428-B2 | Etchant, replenishment solution and method for forming copper wiring | MEC COMPANY LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20170260632-A1 | ETCHANT, REPLENISHMENT SOLUTION AND METHOD FOR FORMING COPPER WIRING | MEC COMPANY LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | DRD4 3620/4885DRD3 4024/4885DRD2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.